Image Sourced ShutterStock
Market Herald logo


Be the first with the news that moves the market
  • Osprey shares have spiked today after the Trump Administration signed an executive order to support kidney health in the US
  • Osprey’s DyeVert technology is aimed at reducing the risk of kidney damage in patients undergoing heart imaging procedures
  • DyeVert is the only US Food and Drug Administration (FDA) approved device for contrast reduction for use in coronary angiograms
  • Roughly 37 million Americans suffer from kidney disease, meaning Osprey is in a strong position to benefit from the new policies

Osprey Medical shares are up 19 per cent today in light of the US Trump Administration signing an executive order to support kidney health in the country.

Osprey is a winner in today’s announcement because of its proprietary ‘DyeVert’ technology, which is aimed at reducing the risk of kidney damage in patients undergoing heart imaging procedures.

The amount of dye — referred to as contrast — used in certain heart imaging procedures can increase a patient’s risk of Contrast-Induced Acute Kidney Injury (CI-AKI). Osprey’s technology helps physicians minimise their dye usage and monitor dosage in real time throughout procedures.

DyeVert reduces contrast while maintaining image quality. It’s also the only US Food and Drug Administration (FDA) approved device for contrast reduction for use in coronary angiograms.

The Trump Administration’s executive order is aimed at providing better and more affordable care for US citizens suffering for various forms of kidney disease.

“Today we’re taking groundbreaking action to bring new hope to millions of Americans suffering from kidney disease,” President Trump said.

The policy is set to improve kidney care in three main areas: preventative and educational measures, more cost-efficient and accessible treatments, and making more kidneys available for transplant.

More specifically, the order has goals to: reduce the number of Americans developing end-stage renal disease by 25 per cent in the next 10 years; see 80 per cent of new patients in 2025 receive dialysis in the home or receive a transplant; and double the number of kidneys available for transplant by 2030.

According to the U.S. Centers for Disease Control and Prevention, roughly 37 million Americans suffer from kidney disease.

This is 15 per cent of the nation’s adults. Furthermore in 2017, kidney disease was the ninth leading case of death in the country.

While the most common form of treatment is dialysis, the Trump Administration said this is far from sustainable and incredibly burdensome. On top of this, there are nearly 100,000 Americans on the waiting list for a kidney transplant.

This is where Osprey comes in.

According to company CEO Mike McCormick, the plan to enhance education and awareness regarding kidney disease makes Osprey well positioned for growth in the U.S. market.

“In the United States, there are over 800,000 coronary angiograms performed each year, with approximately 25 per cent of patients undergoing these procedures also having Chronic Kidney Disease (CKD), and who are at risk of CI-AKI,” Mike explained.

He said there is growing evidence that Osprey’s DyeVert platform can drastically reduce CI-AKI rates.

“Coronary angiogram patients who develop CI-AKI are hospitalised longer and have significantly higher mortality rates,” he said.

As such, as part of the new government policies, Osprey’s technology could prove to be highly beneficial to both patients suffering from kidney diseases and the company itself.

As at 11:51am AEST, Osprey shares are trading for 7.4 cents each compared to yesterday’s close of 6.2 cents each. Osprey shares are trading in a $31.95 million market cap.

OSP by the numbers
More From The Market Herald
Heramed (ASX:HMD) - CEO and Co Founder, David Groberman

" HeraMED (ASX:HMD) raises $2.39m via convertible note placement

HeraMED (HMD) has raised roughly $2.39 million through a convertible note placement.
NeuroScientific Biopharmaceuticals (ASX:NSB) - MD and CEO, Matthew Liddelow

" NeuroScientific Biopharmaceuticals (ASX:NSB) completes safety pharmacology studies

NeuroScientific Biopharmaceuticals (NSB) has seen no adverse events during its non-clinical studies of EmtinB.
PharmAust (ASX:PAA) - Chief Scientific Officer, Dr Richard Mollard

" PharmAust (ASX:PAA) identifies optimal MPL dose for canine cancer

Clinical-stage biotech company PharmAust (PAA) has identified the optimum monepantel (MPL) drug plasma range for dogs with B-cell lymphoma.
Alcidion Group (ASX:ALC) - Group Managing Director, Kate Quirke

" Alcidion Group (ASX:ALC) extends contract with Sydney Local Health District

Alcidion Group (ALC) has expanded the use of its remote patient monitoring platform, Miya Precision, with the Sydney Local Health District (LHD).